A carrier for targeted chemotherapy drug
Researchers have proposed the use of polyoxometallate nanoclusters as a carrier for chemotherapy drug. It will help to deliver medications precisely to the focus of a pathological process, such as a cancerous tumor, without toxic effects on healthy cells. Delivery can be accomplished either by electrophoresis or by injection into the bloodstream.

It is polyatomic ions composed of molybdenum and iron, joined together by common oxygen atoms, containing organic groups. Their peculiarity is that they are a nanocluster to the surface of which a medication can be attached and delivered to the tumor formation. Polyoxometallates themselves are not toxic to living cells and do not change their function or morphology. On the contrary, cells are able to absorb these nanocapsules without any harm. Polyoxometallates give in the body of warm-blooded animals the effect of increasing the hemoglobin level and the number of red blood cells, which allows to use them for the treatment and prevention of anemia.

They tested how the nanocluster would interact with doxorubicin. This is a well-known anticancer antibiotic. It is good at destroying tumor structures, but has low selectivity. High concentrations of the medication needed to destroy cancer cells are toxic to the weakened body. Scientists figured out how a polyoxometallate with an antibiotic inside would affect healthy and tumor cells and selected the most effective concentration of the medication.

Source: https://www.eurekalert.org/news-releases/951113